Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit

Table 2 Worldwide prevalence of Meropenem-resistant Pseudomonas Aeruginosa, n %

Continent	Country	Prevalence	Site of infection	Ref.
Africa	Egypt	41.82-78	Mix	[83,84]
	Lebanon	42.9	Mix	[83]
	Libya	46	Mix	[83]
	Tunisia	53.71	Mix	[83]
	Uganda	88.8	Mix	[83]
America	Brazil	22.9-51.8	Mix	[85,86]
	Canada	18.3	Mix	[41]
	Costa Rica	91.3	Ns	[48]
	United States	12.9-43.3	Mix	[87,88]
Asia	Indonesia	12.4-38.1	Mix	[89,90]
	Indonesia	12.4-38.1	Mix	[89,90]
	Iran	25	BSI	[91]
	Korea	50-92.9	BSI	[49,92]
	Qatar	85.7	Mix	[93]
	Saudi Arabia	52.5	Mix	[83]
	Taiwan	22.5	Mix	[94]
	United Arab Emirates	7.7	Mix	[83]
	Turkey	46.7	Mix	[95]
Europe	Germany	61-66.7	Mix	[47,75]
	Netherlands	8.3-17	Mix	[46]
	Serbia	65.1	HAC	[81]
		70.2	VAP
	Switzerland	27	Mix	[51]

¹Authors used carbapenems other than Meropenem or do not specify the carbapenem tested.

BSI: Bloodstream infections; VAP: Ventilator-associated pneumonia; HAC: Hospital-acquired condition; NS: Not specified; Mix: More than one infection site or aggregated data about them.